The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT).
 
Darren R. Feldman
Research Funding - Decibel Therapeutics (Inst); Novartis; Seagen
Other Relationship - UpToDate
 
James S Hu
Honoraria - Eisai
Consulting or Advisory Role - Eisai
Speakers' Bureau - Eisai
Travel, Accommodations, Expenses - Eisai
 
Sujata Patil
No Relationships to Disclose
 
Victor E. Reuter
No Relationships to Disclose
 
Sandy Srinivas
Consulting or Advisory Role - Genentech/Roche
Speakers' Bureau - Genentech
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech (Inst); Merck (Inst)
 
Walter Michael Stadler
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; CVS Caremark; Eisai; Merck; Pfizer; Roche/Genentech; Sotio
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Clovis Oncology (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Johnson & Johnson (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Seagen (I); Tesaro (Inst); X4 Pharma (Inst)
Other Relationship - American Cancer Society; UpToDate
 
Brian Addis Costello
Research Funding - GlaxoSmithKline/Novartis (Inst)
 
Matthew I. Milowsky
Consulting or Advisory Role - BioClin Therapeutics
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); X4 Pharma (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
Other Relationship - Asieris Pharmaceuticals
 
Leonard Joseph Appleman
Research Funding - Acerta Pharma (Inst); Agensys (Inst); Astellas Pharma (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Inovio Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tokai Pharmaceuticals (Inst)
 
Tanya B. Dorff
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; EMD Serono; Janssen Oncology; Roche
Speakers' Bureau - Exelixis; Pfizer; Prometheus
Research Funding - Bayer; Bristol-Myers Squibb
 
Maria Bromberg
No Relationships to Disclose
 
Gabriella Joseph
No Relationships to Disclose
 
Samuel Aaron Funt
Stock and Other Ownership Interests - Allogene Therapeutics; Hubble (I); Kite, a Gilead company; Neogene Therapeutics (I); Second Science; Urogen pharma (I)
Consulting or Advisory Role - MedImmune
Research Funding - AstraZeneca; Genentech/Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Dean F. Bajorin
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EMD Serono; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Lilly; Merck; Novartis; Pfizer; Roche; Roche/Genentech; Urogen pharma
Research Funding - Amgen (Inst); Astellas Pharma; AstraZeneca; Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Roche/Genentech; Urogen pharma
 
George J. Bosl
No Relationships to Disclose
 
David I. Quinn
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Dendreon; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Mundipharma; Novartis; Pfizer; Pharmacyclics; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Dendreon; Eisai; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi; US Biotest
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Sanofi (Inst)
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Incyte; Lilly; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); Novartis (Inst); Pfizer (Inst)